Han Lee, Ph.D., is co-CEO of Vibrant Therapeutics, a clinical-stage biotech building logic-gated, conditionally activated antibody prodrugs designed to switch on only inside diseased tissue. A Yale-trained geneticist with an MBA who can read a sequencing run and a term sheet with equal fluency, Lee spent 15 years as the finance and dealmaking engine behind cell-therapy companies - Arcellx, Neogene, and ImmPACT Bio - steering more than 75 transactions worth billions, including two startup exits to AstraZeneca and Lyell Immunopharma. In January 2026 he joined founder Larry Wang to scale Vibrant globally and push its lead masked T-cell engager, VIB305, into the clinic.
Rami Elghandour is Chairman and CEO of Arcellx (NASDAQ: ACLX), a clinical-stage biotechnology company developing next-generation cell therapies for cancer and autoimmune diseases. An engineer turned venture capitalist turned serial CEO, he has led two successful IPOs, built two multibillion-dollar public companies, and raised over $1.75 billion in capital. At Arcellx, he transformed the company from an early-stage startup into a commercial-ready organization with a peak valuation exceeding $6 billion, advancing the anito-cel BCMA CAR-T therapy toward FDA approval for relapsed/refractory multiple myeloma. A TEDx speaker on unconscious bias and gender equity, Rami is also an executive producer of the Oscar-nominated documentary 'The Voice of Hind Rajab' and the Sundance-premiered 'American Doctor.'